ERS International Congress 2023: highlights from the Interstitial Lung Diseases Assembly.

This article summarises a selection of scientific highlights in the field of interstitial lung diseases (ILDs) presented at the International Congress of the European Respiratory Society in 2023. Translational and clinical studies focused on the whole spectrum of ILDs, from (ultra)rare ILDs to sarcoidosis, ILDs associated with connective tissue disease and idiopathic pulmonary fibrosis. The main topics of the 2023 Congress presentations were improving the diagnostic process of ILDs, better prediction of disease course and investigation of novel treatment options.
Competing Interests: Conflict of interest: L. Fabbri, J. Guiot and E. Bargagli have nothing to disclose. Conflict of interest: M. Vermant reports travel fees from Sanofi, outside the submitted work. Conflict of interest: E. Miądlikowska reports travel fees from Boehringer Ingelheim, outside the submitted work. Conflict of interest: D. Estrella reports travel fees from Sanofi and Roche/Genentech outside the submitted work. Conflict of interest: M.S. Wijsenbeek reports grants from Boehringer Ingelheim and Hoffmann la Roche, and fees from Bristol Myers Squibb, Boehringer Ingelheim, Galapagos, Galecto, Hoffman la Roche, Horizon Therapeutics, Kinevant Sciences, Molecure, Nerre Therapeutics, Novartis, PureTech Health, Respivant and CSL Behring, outside the submitted work, paid to her institution. Conflict of interest: W. Wuyts reports grants and fees from Boehringer Ingelheim, Hoffman la Roche, Galapagos and Sanofi, outside the submitted work, paid to his institution. Conflict of interest: A. Froidure reports grants and fees from Boehringer Ingelheim. Conflict of interest: P. Spagnolo reports grants from PPM Services, Roche and Boehringer Ingelheim, outside the submitted work, paid to his institution; and fees from PPM Services, Novartis, Pieris, Glycocore Pharma, Galapagos, Boehringer Ingelheim and Menarini outside the submitted work. Conflict of interest: M. Veltkamp reports fees from Boehringer Ingelheim and Chiesi outside the submitted work. Conflict of interest: M. Molina-Molina reports grants and fees from Boehringer Ingelheim, Roche, Chiesi and Ferrer, outside the submitted work. Conflict of interest: C. McCarthy reports grants and fees from Boehringer Ingelheim, Savara Inc., AI Therapeutics and Theravance Inc., outside the submitted work. Conflict of interest: K. Antoniou reports grants and fees from Boehringer Ingelheim, Hoffmann la Roche, GlaxoSmithKline, AstraZeneca, Chiesi and Menarini outside the submitted work. Conflict of interest: M. Kreuter reports grants and fees from Boehringer Ingelheim, Hoffman la Roche and Nichtraucherhelden/Sanero outside the submitted work. Conflict of interest: C.C. Moor reports grants and fees from Boehringer Ingelheim, Hoffmann la Roche, AstraZeneca and Daiichi Sankyo, outside the submitted work, paid to her institution.
(Copyright ©The authors 2024.)